Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shaoyao Shujin
- Development stage
- Unknown
- Lead developer
- Fosun Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Shaoyao Shujin is a Traditional Chinese Medicine (TCM) granule formulation developed by Shanghai Traditional Chinese Medicine University Yuanchuang Technology Co., Ltd. for the treatment of knee osteoarthritis (KOA). The drug is based on the traditional "Shaoyao" (Paeonia) herb, which is recognized in TCM for its ability to nourish blood and alleviate pain by relaxing tendons. Pharmacologically, Shaoyao Shujin is designed to inhibit inflammatory pathways, specifically targeting pro-inflammatory cytokines like Interleukin-1 beta (IL-1β) and Tumor necrosis factor (TNF), as well as the enzyme Cyclooxygenase-2 (COX-2). These actions help to reduce synovial inflammation, alleviate joint pain, and potentially slow the progression of cartilage degradation. As of 2024, the drug is in Phase 3 clinical development in China, following successful Phase 2 trials that demonstrated its safety and efficacy in improving joint function and reducing symptoms in patients with KOA.
- Brand names
- Shaoyao Shujin
- Other names
- Shaoyao Shujin Granules芍药舒筋颗粒
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))PTGS2 (Prostaglandin-Endoperoxide Synthase 2)IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on Shaoyao Shujin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shaoyao Shujin.